{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:34:49Z","timestamp":1793298889705,"version":"4.5.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To systematically review the evidence for the effectiveness and safety of magnesium sulfate as a fetal neuroprotective agent when given to individuals at risk of preterm birth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES:<\/jats:title>\n                    <jats:p>We searched Cochrane Pregnancy and Childbirth's Trials Register, ClinicalTrials.gov, the World Health Organization International Clinical Trials Registry Platform (through March 17, 2023), and reference lists of relevant studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS OF STUDY SELECTION:<\/jats:title>\n                    <jats:p>Randomized controlled trials (RCTs) assessing magnesium sulfate for fetal neuroprotection in pregnant participants at risk of imminent preterm birth were eligible. Two authors assessed RCTs for inclusion, extracted data, and evaluated risk of bias, trustworthiness, and evidence certainty (GRADE [Grading of Recommendations Assessment, Development and Evaluation]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TABULATION, INTEGRATION, AND RESULTS:<\/jats:title>\n                    <jats:p>We included six RCTs (5,917 pregnant participants and 6,759 fetuses at less than 34 weeks of gestation at randomization). They were conducted in high-income countries (two in the United States, two across Australia and New Zealand, and one each in Denmark and France) and commenced between 1995 and 2018. Primary outcomes: up to 2 years of corrected age, magnesium sulfate compared with placebo reduced the risk of cerebral palsy (risk ratio [RR] 0.71, 95% CI, 0.57\u20130.89; six RCTs, 6,107 children) and death or cerebral palsy (RR 0.87, 95% CI, 0.77\u20130.98; six RCTs, 6,481 children) (high-certainty evidence). Magnesium sulfate had little or no effect on death up to 2 years of corrected age (moderate-certainty evidence) or these outcomes at school age (low-certainty evidence). Although there was little or no effect on death or cardiac or respiratory arrest for pregnant individuals (low-certainty evidence), magnesium sulfate increased adverse effects severe enough to stop treatment (RR 3.21, 95% CI, 1.88\u20135.48; three RCTs, 4,736 participants; moderate-certainty evidence). Secondary outcome: magnesium sulfate reduced the risk of severe neonatal intraventricular hemorrhage (moderate-certainty evidence).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Magnesium sulfate for preterm fetal neuroprotection reduces cerebral palsy and death or cerebral palsy for children. Further research is required on longer-term benefits and harms for children, effect variation by participant and treatment characteristics, and the generalizability of findings to low- and middle-income countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SYSTEMATIC REVIEW REGISTRATION:<\/jats:title>\n                    <jats:p>The review protocol was based on a standard Cochrane Pregnancy and Childbirth template and our previous Cochrane Systematic Review (doi: 10.1002\/14651858.CD004661.pub3; published before the introduction of PROSPERO).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000005644","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T17:04:13Z","timestamp":1717434253000},"page":"161-170","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":21,"title":["Magnesium Sulfate Before Preterm Birth for Neuroprotection"],"prefix":"10.1097","volume":"144","author":[{"given":"Emily S.","family":"Shepherd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shona","family":"Goldsmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lex W.","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippa","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Marret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwight J.","family":"Rouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Pryde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne T.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline A.","family":"Crowther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"key":"R1-20260826","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/dmcn.15346","article-title":"Global prevalence of cerebral palsy: a systematic analysis","volume":"64","author":"McIntyre","year":"2022","journal-title":"Dev Med Child Neurol"},{"key":"R2-20260826","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/088307389200700113","article-title":"Maternal toxemia is associated with reduced incidence of germinal matrix hemorrhage in premature babies","volume":"7","author":"Kuban","year":"1992","journal-title":"J Child Neurol"},{"key":"R3-20260826","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1542\/peds.95.2.263","article-title":"Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants?","volume":"95","author":"Nelson","year":"1995","journal-title":"Pediatrics"},{"key":"R4-20260826","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3109\/01443615.2011.638999","article-title":"Treatment with magnesium sulphate in pre-term birth: a systematic review and meta-analysis of observational studies","volume":"32","author":"Wolf","year":"2012","journal-title":"J Obstet Gynaecol"},{"key":"R5-20260826","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1067\/mob.2002.123544","article-title":"Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants","volume":"186","author":"Mittendorf","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"R6-20260826","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1001\/jama.290.20.2669","article-title":"Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial","volume":"290","author":"Crowther","year":"2003","journal-title":"JAMA"},{"key":"R7-20260826","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1471-0528.2006.01162.x","article-title":"Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial","volume":"114","author":"Marret","year":"2007","journal-title":"BJOG"},{"key":"R8-20260826","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa0801187","article-title":"A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy","volume":"359","author":"Rouse","year":"2008","journal-title":"N Engl J Med"},{"key":"R9-20260826","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/AOG.0b013e3181ae98c2","article-title":"Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis","volume":"114","author":"Costantine","year":"2009","journal-title":"Obstet Gynecol"},{"key":"R10-20260826","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ajog.2009.04.005","article-title":"Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis","volume":"200","author":"Conde-Agudelo","year":"2009","journal-title":"Am J Obstet Gynecol"},{"key":"R11-20260826","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1097\/AOG.0b013e3181a60495","article-title":"Antenatal magnesium sulfate and neurologic outcome in preterm infants: a systematic review","volume":"113","author":"Doyle","year":"2009","journal-title":"Obstet Gynecol"},{"key":"R12-20260826","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004661.pub3","article-title":"Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus","author":"Doyle","year":"2009","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"R13-20260826","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/AOG.0b013e3181d4ffa5","article-title":"Magnesium sulfate before anticipated preterm birth for neuroprotection. Committee Opinion No. 455. American College of Obstetricians and Gynecologists","volume":"115","year":"2010","journal-title":"Obstet Gynecol"},{"key":"R14-20260826","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1515\/jpm-2018-0174","article-title":"Antenatal magnesium sulfate for fetal neuroprotection: a critical appraisal and systematic review of clinical practice guidelines","volume":"47","author":"Jayaram","year":"2019","journal-title":"J Perinat Med"},{"key":"R16-20260826","doi-asserted-by":"crossref","first-page":"e1002398","DOI":"10.1371\/journal.pmed.1002398","article-title":"Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: an individual participant data meta-analysis","volume":"14","author":"Crowther","year":"2017","journal-title":"PLoS Med"},{"key":"R17-20260826","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R18-20260826","article-title":"Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus","author":"Shepherd","year":"2024","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"R22-20260826","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/1471-0528.16239","article-title":"Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial","volume":"127","author":"Wolf","year":"2020","journal-title":"BJOG"},{"key":"R23-20260826","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2023.12357","article-title":"Prenatal intravenous magnesium at 30-34 weeks' gestation and neurodevelopmental outcomes in offspring: the MAGENTA randomized clinical trial","volume":"330","author":"Crowther","year":"2023","journal-title":"JAMA"},{"key":"R24-20260826","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jpeds.2014.04.007","article-title":"School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants","volume":"165","author":"Chollat","year":"2014","journal-title":"J Pediatr"},{"key":"R25-20260826","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jama.2014.11189","article-title":"School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo","volume":"312","author":"Doyle","year":"2014","journal-title":"JAMA"},{"key":"R26-20260826","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/1471-0528.16238","article-title":"Magnesium sulphate for fetal neuroprotection at imminent risk for preterm delivery: a systematic review with meta-analysis and trial sequential analysis","volume":"127","author":"Wolf","year":"2020","journal-title":"BJOG"},{"key":"R27-20260826","doi-asserted-by":"crossref","first-page":"e2451","DOI":"10.1097\/MD.0000000000002451","article-title":"Effects and safety of magnesium sulfate on neuroprotection: a meta-analysis based on PRISMA guidelines","volume":"95","author":"Zeng","year":"2016","journal-title":"Medicine"},{"key":"R28-20260826","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1471-0528.2006.01165.x","article-title":"The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months","volume":"114","year":"2007","journal-title":"BJOG"},{"key":"R29-20260826","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/1471-2393-13-195","article-title":"Maternal adverse effects of different antenatal magnesium sulphate regimens for improving maternal and infant outcomes: a systematic review","volume":"13","author":"Bain","year":"2013","journal-title":"BMC Pregnancy Childbirth"},{"key":"R30-20260826","doi-asserted-by":"crossref","first-page":"e1002988","DOI":"10.1371\/journal.pmed.1002988","article-title":"Antenatal magnesium sulphate and adverse neonatal outcomes: a systematic review and meta-analysis","volume":"16","author":"Shepherd","year":"2019","journal-title":"PLoS Med"},{"key":"R31-20260826","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2023.21723","article-title":"Prenatal intravenous magnesium and neurodevelopmental outcomes in offspring","volume":"330","author":"Marret","year":"2023","journal-title":"JAMA"},{"key":"R32-20260826","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.3390\/children10081324","article-title":"School-age outcomes of antenatal magnesium sulphate in preterm infants","volume":"10","author":"Kobayashi","year":"2023","journal-title":"Children"},{"key":"R33-20260826","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/jamapediatrics.2017.1689","article-title":"Early, accurate diagnosis and early intervention in cerebral palsy: advances in diagnosis and treatment","volume":"171","author":"Novak","year":"2017","journal-title":"JAMA Pediatr"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005644","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:03:00Z","timestamp":1787742180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005644"}},"subtitle":["An Updated Cochrane Systematic Review"],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000005644","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,3]]},"assertion":[{"value":"2024-03-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}